tasosartan

01/01/1999 - "These results demonstrate that tasosartan at 50 to 200 mg given once a day over a titration period of 10 weeks was effective and safe in the treatment of essential hypertension."
04/01/1998 - "A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. "
03/01/2000 - "The primary objective of this study was to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of tasosartan and atenolol administered alone and concomitantly under steady-state conditions in 17 patients ages 18 to 65 years diagnosed with stage 1 to 2 essential hypertension. "
03/01/2000 - "A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension."
12/01/1998 - "Evaluate the effects of 2 weeks of treatment with tasosartan (1) on cardiac function at rest and during submaximal exercise, (2) on exercise peak oxygen uptake, and (3) on regional haemodynamics at rest in a control condition and during the recovery period of submaximal exercise in patients with essential hypertension. "

01/01/1999 - "In this double-blind, randomized, dose-titration, multicenter trial, tasosartan and placebo were compared in patients with stage I and stage II hypertension. "
04/01/1998 - "Discontinuation of tasosartan therapy was not associated with rebound hypertension. "